FDA approves long-acting injectable for schizophrenia and bipolar disorder
European Pharmaceutical Review
JANUARY 16, 2023
The US Food and Drug Administration (FDA) has approved Rykindo ® (risperidone) for extended-release injectable suspension. The drug is indicated as a bi-weekly treatment for schizophrenia and as monotherapy or as adjunctive therapy to lithium or valproate for bipolar I disorder in adults.
Let's personalize your content